HbA1c After a Short Period of Monotherapy With Metformin Identifies Durable Glycemic Control Among Adolescents With Type 2 Diabetes
Year: 2015
Type: article
Abstract: OBJECTIVE: To determine whether clinically accessible parameters early in the course of youth-onset type 2 diabetes predict likelihood of durable control on oral therapy. RESEARCH DESIGN AND METHODS: TODAY was a randomized clinical trial of adolescents with type 2 diabetes. Two groups, including participants from all three treatments, were defined for analysis: (1) those who remained in glycemic control for at least 48 months of follow-up and (2) those who lost glycemic control before 48 months. Outcome group was analyzed in univariate and multivariate models as a function of baseline characteristics (age, sex, race/ethnicity, socioeconomic status, BMI, waist circumference, Tanner stage, disease duration, depressive symptoms) and biochemical measures (HbA1c, C-peptide, lean and fat body mass, insulin inverse, insulinogenic index). Receiver operating characteristic curves were used to analyze HbA1c cut points. RESULTS: In multivariate models including factors significant in univariate analysis, only HbA1c and insulinogenic index at randomization remained significant (P < 0.0001 and P = 0.0002, respectively). An HbA1c cutoff of 6.3% (45 mmol/mol) (positive likelihood ratio [PLR] 3.7) was identified that optimally distinguished the groups; sex-specific cutoffs were 6.3% (45 mmol/mol) for females (PLR 4.4) and 5.6% (38 mmol/mol) for males (PLR 2.1). CONCLUSIONS: Identifying youth with type 2 diabetes at risk for rapid loss of glycemic control would allow more targeted therapy. HbA1c is a clinically accessible measure to identify high risk for loss of glycemic control on oral therapy. Adolescents with type 2 diabetes unable to attain a non-diabetes range HbA1c on metformin are at increased risk for rapid loss of glycemic control.
Source: Diabetes Care
DOI: 10.2337/dc15-0848
Authors: Phil Zeitler, Kathryn Hirst, Kenneth C. Copeland, Laure El ghormli, Lorraine Levitt Katz, Lynne L. Levitsky, Barbara Linder, Paul McGuigan, Neil H. White, Denise Wilfley, for the TODAY Study Group
Institutions: University of Colorado Anschutz, University of Colorado Denver, George Washington University, University of Oklahoma, Children's Hospital of Philadelphia, University of Pennsylvania, Harvard University, Massachusetts General Hospital, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Rainbow Babies & Children's Hospital, Case Western Reserve University, Washington University in St. Louis
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: General Clinical Research Center, Management of Pediatric Type 2 Diabetes Mellitus, Multi-Center Study of the Treatment of T2DM in Youth, Case Western Reserve University/Cleveland Clinic CTSA (UL1), Harvard Clinical and Translational Science Center (UL1), General Clinical Research Center, University of Pittsburgh Clinical and Translational Science Institute, Type 2 Diabetes in Youth: Beta Cell Preservation, Treatment Alternatives in Pediatric Type 2 Diabetes, TODAY2 Phase 2 (T2P2): Long-Term Post-Intervention Follow-Up, Institutional Clinical and Translational Science Award, Colorado Clinical and Translational Sciences Institute, General Clinical Research Center, General Clinical Research Center, General Clinical Research Center, Washington University Institute of Clinical and Translational Sciences, Washington University Institute of Clinical and Translational Sciences (UL1), Yale University Clinical and Translational Science Award Program, General Clinical Research Center, The Washington University Center for Diabetes Translation Research, GENERAL CLINICAL RESEARCH CENTER, Colorado Clinical and Translational Science Institute (UL1)
OpenAlex ID: W2176173337
